Deep knowledge on
small-molecule drugs and
the 90,000 global patents
covering them

Start your free trial now

Instant access. No credit card. No commitment.

Plans and Pricing

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: TAZORAC

« Back to Dashboard
Tazorac is a drug marketed by Allergan and is included in two NDAs. It is available from two suppliers.

The generic ingredient in TAZORAC is tazarotene. There are seven drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the tazarotene profile page.

Summary for Tradename: TAZORAC

Patents:0
Applicants:1
NDAs:2
Suppliers: see list2

Pharmacology for Tradename: TAZORAC

Ingredient-typeRetinoids
Drug ClassRetinoid

Clinical Trials for: TAZORAC

A Study Comparing Tazarotene Cream 0.1% to Tazorac® and Both to a Placebo Control in the Treatment of Acne Vulgaris
Status: Completed Condition: Acne Vulgaris

Generic Tazarotene Cream, 0.05% for the Treatment of Plaque Psoriasis
Status: Recruiting Condition: Plaque Psoriasis

Safety, Tolerability and Pharmacokinetics of AGN-190168 in Subjects With Acne Vulgaris
Status: Completed Condition: Acne Vulgaris

Efficacy and Safety Study of Tazarotene (Tazorac) for the Treatment of Brittle Nails
Status: Completed Condition: Brittle Nails

Differin® Gel x12 Wks vs Tazorac® Cream x12 Wks vs Differin® x6 Wks Switched to Tazorac® x6 Wks for Treatment of Acne
Status: Completed Condition: Acne Vulgaris

A Study to Evaluate the Bioavailability of Tazarotene Foam, 0.1%, and Tazorac Gel, 0.1%, in Subjects With Acne Vulgaris
Status: Completed Condition: Acne Vulgaris

Generic Tazarotene Cream, 0.1% in the Treatment of Acne Vulgaris
Status: Recruiting Condition: Acne Vulgaris

A Study to Evaluate the Potential of Tazarotene Foam to Cause a Reaction When Applied to the Skin and Exposed to Light on Healthy Volunteers
Status: Completed Condition: Acne Vulgaris

A Phase 4, Single-Blind, Randomized, Study to Compare the Tolerability and Efficacy of 0.1% Tazorac Cream When Used in Combination With Either Duac Gel or Acanya Gel for the Treatment of Facial Acne Vulgaris
Status: Completed Condition: Acne Vulgaris

Tazarotene 0.1% Cream For the Treatment of Cutaneous T-Cell Lymphoma: A Prospective Study
Status: Recruiting Condition: Cutaneous T-Cell Lymphoma

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Allergan
TAZORAC
tazarotene
CREAM;TOPICAL021184-001Sep 29, 2000RXYes<disabled><disabled>
Allergan
TAZORAC
tazarotene
GEL;TOPICAL020600-002Jun 13, 1997RXYes<disabled><disabled>
Allergan
TAZORAC
tazarotene
CREAM;TOPICAL021184-002Sep 29, 2000RXYes<disabled><disabled>
Allergan
TAZORAC
tazarotene
GEL;TOPICAL020600-001Jun 13, 1997RXYes<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn
`abc